The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

BTOG 2020 | Actionable lung cancer targets

Name: Actionable lung cancer targets
Uploaded: 2020-01-30T00:00:00Z
Duration: 5 min 8 s
Description: Stephen Liu, MD, MedStar Georgetown University Hospital, Washington, DC, actionable targets for the treatment of non-small cell lung cancer (NSCLC), such as MET and RET. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

Stephen Liu • 30 Jan 2020

BTOG 2020

Lung Cancer Non-Small Cell Lung Cancer Capmatinib Crizotinib Larotrectinib Tepotinib

Stephen Liu, MD, MedStar Georgetown University Hospital, Washington, DC, actionable targets for the treatment of non-small cell lung cancer (NSCLC), such as MET and RET. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.